Vitamin D levels vary during antiviral treatment but are unable to predict treatment outcome in HCV genotype 1 infected patients

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Grammatikos, Georgios ^a   Lange, Christian ^a   Susser, Simone ^a   Schwendy, Susanne ^b   Dikopoulos, Nektarios ^c   Buggisch, Peter ^d   Encke, Jens ^e   Teuber, Gerlinde ^f   Goeser, Tobias ^g   Thimme, Robert ^h   Klinker, Hartwig ⁱ   Boecher, Wulf O ^j   Schulte Frohlinde, Ewert ^b   Penna Martinez, Marissa ^a   Badenhoop, Klaus ^a   Zeuzem, Stefan ^a   Berg, Thomas ^k   Sarrazin, Christoph ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY HOSPITAL ULM   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^f Interdisziplinäres Facharztzentrum Sachsenhausen   (Germany)

^g UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^h UNIVERSITY OF FREIBURG   (Germany)

ⁱ UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^j UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^k UNIVERSITY HOSPITAL LEIPZIG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; 7 DEHYDROCHOLESTEROL REDUCTASE; CHOLESTEROL; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; INTERLEUKIN 28B; OXIDOREDUCTASE; PEGINTERFERON ALPHA; RIBAVIRIN; UNCLASSIFIED DRUG; 25-HYDROXYVITAMIN D; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN; VITAMIN D;

ADULT; AGE; AGED; ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; DHCR7 TT GENE; FEMALE; GENETIC ASSOCIATION; GGT GENE; HEPATITIS; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; IL28B GENE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHARMACOGENETICS; PREDICTION; PROGNOSIS; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; VITAMIN BLOOD LEVEL; ADOLESCENT; ANALOGS AND DERIVATIVES; BLOOD; GENETICS; HEPACIVIRUS; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME; VITAMIN D; YOUNG ADULT;

EID: 84895520347     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087974     Document Type: Article

References (37)

1. Neal KR, Ramsay S, Thomson BJ, Irving WL (2007) Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study. Gut 56: 1098-1104. (Pubitemid 47123240)
2. Sarrazin C, Berg T, Cornberg M, Dollinger M, Ferenci P, et al. (2012) Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C. Z Gastroenterol 50: 57-72.
3. Kau A, Vermehren J, Sarrazin C (2008) Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 49: 634-651.
4. Weich V, Herrmann E, Chung TL, Sarrazin C, Hinrichsen H, et al. (2011) The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection. J Gastroenterol 46: 1427-1436.
5. Corey KE, Kane E, Munroe C, Barlow LL, Zheng H, et al. (2009) Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology 50: 1030-1037.
6. Berg T, Weich V, Teuber G, Klinker H, Moller B, et al. (2009) Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. Hepatology 50: 369-377.
7. Lee S, Varano J, Flexman JP, Cheng W, Watson MW, et al. (2010) Decreased IP-10 and elevated TGFbeta1 levels are associated with viral clearance following therapy in patients with hepatitis C virus. Dis Markers 28: 273-280.
8. Lange CM, Kutalik Z, Morikawa K, Bibert S, Cerny A, et al. (2012) Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy. Hepatology 55: 1038-1047.
9. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401.
10. Bitetto D, Fattovich G, Fabris C, Ceriani E, Falleti E, et al. (2011) Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepatology 53: 1118-1126.
11. Abu-Mouch S, Fireman Z, Jarchovsky J, Zeina AR, Assy N (2011) Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naive patients. World J Gastroenterol 17: 5184-5190.
12. Falleti E, Bitetto D, Fabris C, Fattovich G, Cussigh A, et al. (2012) Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C. Hepatology 56: 1641-50.
13. Petta S, Camma C, Scazzone C, Tripodo C, Di M, et al. (2010) Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology 51: 1158-1167.
14. Petta S, Ferraro D, Camma C, Cabibi D, Di CA, et al. (2012) Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C. Antivir Ther 17: 823-31.
15. Lange CM, Bibert S, Kutalik Z, Burgisser P, Cerny A, et al. (2012) A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C. PLoS One 7: e40159.
16. Milazzo L, Mazzali C, Bestetti G, Longhi E, Foschi A, et al. (2011) Liver-related factors associated with low vitamin D levels in HIV and HIV/HCV coinfected patients and comparison to general population. Curr HIV Res 9: 186-193.
17. Terrier B, Carrat F, Geri G, Pol S, Piroth L, et al. (2011) Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis. J Hepatol 55: 756-761.
18. Rosen CJ (2011) Clinical practice. Vitamin D insufficiency. N Engl J Med 364: 248-254.
19. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, et al. (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96: 1911-1930.
20. Cooper JD, Smyth DJ, Walker NM, Stevens H, Burren OS, et al. (2011) Inherited variation in vitamin D genes is associated with predisposition to autoimmune disease type 1 diabetes. Diabetes 60: 1624-1631.
21. Dong LM, Ulrich CM, Hsu L, Duggan DJ, Benitez DS, et al. (2009) Vitamin D related genes, CYP24A1 and CYP27B1, and colon cancer risk. Cancer Epidemiol Biomarkers Prev 18: 2540-2548.
22. Lange CM, Bojunga J, Ramos-Lopez E, von WM, Hassler A, et al. (2011) Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol 54: 887-893.
23. Baur K, Mertens JC, Schmitt J, Iwata R, Stieger B,et al. (2012) The vitamin D receptor gene bAt (CCA) haplotype impairs the response to pegylated-interferon/ribavirin-based therapy in chronic hepatitis C patients. Antivir Ther 17: 541-547.
24. Sarrazin C, Schwendy S, Moller B, Dikopoulos N, Buggisch P, et al. (2011) Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks. Gastroenterology 141: 1656-1664.
25. Sarrazin C, Susser S, Doehring A, Lange CM, Muller T, et al. (2011) Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 54: 415-421.
26. Penna-Martinez M, Ramos-Lopez E, Stern J, Kahles H, Hinsch N, et al. (2012) Impaired Vitamin D activation and association with CYP24A1 haplotypes in differentiated thyroid carcinoma. Thyroid 22: 709-16.
27. Rose K, Penna-Martinez M, Klahold E, Karger D, Shoghi F, et al. (2013) Influence of the vitamin D plasma level and vitamin D-related genetic polymorphisms on the immune status of patients with type 1 diabetes: a pilot study. Clin Exp Immunol 171: 171-185.
28. Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, et al. (2010) Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 376: 180-188.
29. Darling JM, Aerssens J, Fanning G, McHutchison JG, Goldstein DB, et al. (2011) Quantitation of pretreatment serum interferon-gamma-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology 53: 14-22.
30. Fattovich G, Covolo L, Bibert S, Askarieh G, Lagging M, et al. (2011) IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. Aliment Pharmacol Ther 33: 1162-1172.
31. Arteh J, Narra S, Nair S (2010) Prevalence of vitamin D deficiency in chronic liver disease. Dig Dis Sci 55: 2624-2628.
32. Fisher L, Fisher A (2007) Vitamin D and parathyroid hormone in outpatients with noncholestatic chronic liver disease. Clin Gastroenterol Hepatol 5: 513-520. (Pubitemid 46575356)
33. Cheng JB, Levine MA, Bell NH, Mangelsdorf DJ, Russell DW (2004) Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc Natl Acad Sci U S A 101: 7711-7715. (Pubitemid 38658094)
34. Petta S, Grimaudo S, Marco VD, Scazzone C, Macaluso FS, et al. (2013) Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients. J Viral Hepat 20: 486-493.
35. Lange CM, Miki D, Ochi H, Nischalke HD, Bojunga J, et al. (2013) Genetic Analyses Reveal a Role for Vitamin D Insufficiency in HCV-Associated Hepatocellular Carcinoma Development. PLoS One 8: e64053.
36. Romero AI, Lagging M, Westin J, Dhillon AP, Dustin LB, et al. (2006) Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis 194: 895-903. (Pubitemid 44454074)
37. Casrouge A, Decalf J, Ahloulay M, Lababidi C, Mansour H, et al. (2011) Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J Clin Invest 121: 308-317.